A. Hollebecque

Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma

Background KRAS mutation is the most common molecular alteration in pancreatic adenocarcinoma (PDAC). However, 8-10% of patients harbor KRAS wild-type tumors (WT). The objectives of this...

A. Hollebecque ;

06/29/2022

Could molecular profiling be helpful in daily practice in the treatment of anal carcinoma?

BackgroundAnal carcinoma (AC) is an uncommon malignancy; however, the incidence has been rising in the past years. Squamous cell carcinoma is the most frequent histological type, related ...

A. Hollebecque ;

06/25/2023

Organoids as tools for functional precision oncology in advanced pancreatic cancer

BackgroundPancreatic ductal adenocarcinoma (PDAC) has a steadily increasing incidence and a poor prognosis, notably due to frequent and early resistance to standard-of-care treatments (SO...

A. Hollebecque ;

06/25/2023

Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma

BackgroundPancreatic cancer is the 7th leading cause of cancer death worldwide and its incidence is on the rise. Chemotherapy with FOLFIRINOX is one of the metastatic first-line reference...

A. Hollebecque ;

06/25/2023

Bidirectional chemotherapy for patients with gastrointestinal peritoneal carcinomatosis

BackgroundPeritoneal carcinomatosis (PC) is a common manifestation in gastro-intestinal (GI) cancers with highest incidence in gastric and colon cancer. Around 20 % of patients developp i...

A. Hollebecque ;

06/25/2023

A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma

IDH1 and 2 (IDH1/2) are mutated in 10-15% of intrahepatic cholangiocarcinoma (CCA). The reversible IDH1 inhibitor ivosidenib is approved in 2L IDH1-mutant CCA. Cisplatin and gemcitabine (...

A. Hollebecque ;

06/25/2023

Impact of molecular profiling on survival in patients with advanced biliary tract cancers

Biliary tract cancers (BTC) are a group of rare cancers (intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], and gallbladder carcinoma [GBC]) that are epidemiolo...

P. Dartigues ;

M. Bani ;

C. Smolenschi ;

J. Scoazec ;

Michel P. Ducreux , MD, PhD;

D. Malka ;

L. Antoun ;

I. Deneche ;

A. Boileve ;

A. Tarabay ;

E. Rouleau ;

A. Hollebecque ;

E. El Rawadi ;

R. Eid ;

L. Lacroix ;

Marc Valery ;

V. Boige ;

06/25/2023

Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study

Fibroblast growth factor receptor 2 ( FGFR2 ) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA). Futibatinib is a highly selective, cova...

A. Hollebecque ;

Arndt Vogel , MD;

06/25/2023

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Background Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metas...

G. Vaccaro ;

D. Melisi ;

R. Al-Rajabi ;

A. Paulson ;

M. Borad ;

D. Gallinson ;

D. Oh ;

E. Dotan ;

Daniel Catenacci , MD;

Eric Van Cutsem , MD, PhD;

A. Murphy ;

C. Lihou ;